Heptares Therapeutics (also known as Heptares) and Kymab Limited have entered into a strategic collaboration to discover, develop and commercialise novel antibody therapeutics.
New therapeutics will target a number of G protein-coupled receptors (GCPRs) with an initial focus on immune-oncology (a new area in the treatment of cancer).
GPCRs are generally expressed on cells of the innate and adaptive immune system. They play a major role in modulating cell migration & recruitment to the tumour environment, activation, survival, production and delineation. They can be targeted by novel immunotherapy antibodies.
To create secure antigens based on various GPCR targets, Heptares will apply its StaR® platform. Kymab will then utilise its Kymouse™ human antibody discovery platform to produce antibodies in response to immunisation with these antigens.
On the other hand, the Kymouse platform provides the possibility of finding the best-in-class antibodies with superior drug properties.
Promising leads will be progressed using the partners' corresponding skills, resources and development capabilities to bring pioneering products into the clinic.
